US 12,433,837 B2
Systems and methods for delivery of a therapeutic agent
Mark E. Deem, Mountain View, CA (US); and Hanson Gifford, Woodside, CA (US)
Assigned to The Foundry, LLC, Menlo Park, CA (US)
Filed by The Foundry, LLC, Menlo Park, CA (US)
Filed on Mar. 3, 2023, as Appl. No. 18/177,875.
Application 12/559,278 is a division of application No. 11/459,090, filed on Jul. 21, 2006, granted, now 7,608,275, issued on Oct. 27, 2009.
Application 18/177,875 is a continuation of application No. 17/151,938, filed on Jan. 19, 2021, granted, now 11,679,077.
Application 17/151,938 is a continuation of application No. 16/842,209, filed on Apr. 7, 2020, granted, now 10,894,011, issued on Jan. 19, 2021.
Application 16/842,209 is a continuation of application No. 16/659,893, filed on Oct. 22, 2019, granted, now 10,610,675, issued on Apr. 7, 2020.
Application 16/659,893 is a continuation of application No. 16/036,381, filed on Jul. 16, 2018, granted, now 10,729,897, issued on Aug. 4, 2020.
Application 16/036,381 is a continuation of application No. 15/358,187, filed on Nov. 22, 2016, granted, now 10,022,529, issued on Jul. 17, 2018.
Application 15/358,187 is a continuation of application No. 14/601,529, filed on Jan. 21, 2015, granted, now 9,498,283, issued on Nov. 22, 2016.
Application 14/601,529 is a continuation of application No. 13/660,629, filed on Oct. 25, 2012, granted, now 8,961,391, issued on Feb. 24, 2015.
Application 13/660,629 is a continuation of application No. 13/253,595, filed on Oct. 5, 2011, granted, now 8,338,164, issued on Dec. 25, 2012.
Application 13/253,595 is a continuation of application No. 12/559,278, filed on Sep. 14, 2009, granted, now 8,133,497, issued on Mar. 13, 2012.
Claims priority of provisional application 60/702,077, filed on Jul. 22, 2005.
Prior Publication US 2023/0285274 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12M 1/00 (2006.01); A61B 18/14 (2006.01); A61B 18/18 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61K 38/48 (2006.01); A61K 41/00 (2020.01); A61M 37/00 (2006.01); A61N 1/08 (2006.01); A61N 1/30 (2006.01); A61N 1/32 (2006.01); A61N 5/10 (2006.01); A61N 7/00 (2006.01); A61B 18/00 (2006.01)
CPC A61K 9/0021 (2013.01) [A61B 18/1492 (2013.01); A61B 18/1815 (2013.01); A61K 9/0078 (2013.01); A61K 38/164 (2013.01); A61K 38/168 (2013.01); A61K 38/4893 (2013.01); A61K 41/00 (2013.01); A61K 41/0028 (2013.01); A61K 41/0047 (2013.01); A61M 37/00 (2013.01); A61M 37/0092 (2013.01); A61N 1/08 (2013.01); A61N 1/303 (2013.01); A61N 1/327 (2013.01); A61N 5/10 (2013.01); A61N 7/00 (2013.01); C12Y 304/24069 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00214 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/1861 (2013.01); A61M 2210/1035 (2013.01); A61N 2007/003 (2013.01); Y02A 50/30 (2018.01)] 18 Claims
 
1. Apparatus for treating tissue in a nasal cavity, the apparatus comprising:
an elongate body, comprising:
a proximal portion; and
a distal portion configured for positioning in a nasal cavity;
a first electrode comprising a first pair of electrodes and a second electrode comprising a second pair of electrodes, the first electrode and second electrode being spaced away from one another and coupled with the distal portion of the elengate body and configured to deliver energy to a target tissue in the nasal cavity; and
a generator coupled with the proximal portion of the elongate body for supplying energy to at least one of the first electrode or the second electrode to treat the target tissue in the nasal cavity, the generator configured to deliver the energy in pulses between 1 V and 500 V.